MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced ...

The human body today has many replaceable parts, ranging from artificial hearts to myoelectric feet. What makes this possible ...

Diedra McCafferty, DO, is the Medical Director for Wound Care and Hyperbaric Medicine at St. Luke’s University Health Network ...

Ohio Valley Surgical Hospital has opened up a new Wound and Hyperbaric Center in Springfield. The new center, which opened last week at 100 W. Main St. on the second floor, is part of an effort to ...

Dr. Greg Vigna Debridement for decubitus ulcers must align with treatment goals, with early reconstructive surgery recommended to avoid ris ...

MediWound has commenced a pivotal, multicentre Phase III VALUE trial to assess its bioactive debridement therapy, EscharEx, for treating venous leg ulcers (VLUs). The primary aim of the trial is to ...

The company said its EscharEx treatment had previously demonstrated its ability to effectively and rapidly remove damaged or ...

Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closureInterim analysis planned ...

Discover a review in which diabetes was investigated in 5 studies, with only one demonstrating a correlation between the ...

Maggot debridement therapy (MDT) is used in septic necrotic wounds ... pressure ulcers, nonhealing surgical wounds, or traumatic wounds [2,3,7]. Nosocomial myiasis is rare [8]. Other predisposing risk ...

Experts from across surgery and healthcare disciplines began working in December on a new classification system for evaluating and reporting surgical site wounds. The idea is to help providers ...